Zoetis Inc (ZTS)
Net profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 2,344,000 | 2,114,000 | 2,037,000 | 1,638,000 | 1,500,000 |
Revenue | US$ in thousands | 8,544,000 | 8,080,000 | 7,776,000 | 6,675,000 | 6,260,000 |
Net profit margin | 27.43% | 26.16% | 26.20% | 24.54% | 23.96% |
December 31, 2023 calculation
Net profit margin = Net income ÷ Revenue
= $2,344,000K ÷ $8,544,000K
= 27.43%
The net profit margin of Zoetis Inc has shown a generally increasing trend over the past five years, indicating the company's ability to efficiently convert revenue into profit. In 2023, the net profit margin reached 27.43%, reflecting a slight improvement from the previous year's margin of 26.16%. This upward trend suggests effective cost management and potentially improving operational efficiency within the company. Zoetis Inc's consistently strong net profit margins compared to previous years demonstrate a stable and profitable business model in the animal health market.
Peer comparison
Dec 31, 2023
Company name
Symbol
Net profit margin
Zoetis Inc
ZTS
27.43%
Abbott Laboratories
ABT
14.51%
AbbVie Inc
ABBV
8.95%
Alkermes Plc
ALKS
21.69%
Amphastar P
AMPH
21.34%
ANI Pharmaceuticals Inc
ANIP
4.13%
Arcus Biosciences Inc
RCUS
-262.39%
Biomarin Pharmaceutical Inc
BMRN
7.06%
Bristol-Myers Squibb Company
BMY
17.83%
Catalent Inc
CTLT
-23.81%
Catalyst Pharmaceuticals Inc
CPRX
17.93%